Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MOF Panel Renews Call for Full Execution of Annual Price Cuts, Urges LLP Copay Review: Budget Proposal
The Fiscal System Council on November 20 issued its recommendation for the FY2024 budget formulation, calling for the full implementation of annual drug price revisions, appropriate rewards for innovation, and the rethink of copay for older medicines. In the recommendation,…
To read the full story
Related Article
- Reward Innovation by Revisiting LLP Copay, Cut Doctor Fees: MOF
November 2, 2023
- JMA Renews Opposition for Health Coverage Review for Pharmaceuticals
June 8, 2023
- MOF Panel Flags Japan’s High Drug Cost per Capita, Stays Pat on Cost-Effectiveness-Based Reimbursement, Copay Review
May 30, 2023
- MOF Panel Nudges Full Annual Drug Re-Pricing, Phase-Out for 2% Buffer Zone
May 26, 2022
- MOF Urges Full Annual Price Cuts, “At Least Stepwise Reductions” in Adjustment Rate
April 14, 2022
- Fiscal Discipline for Drug Spending Could Be Discussed towards FY2023: MOF Budget Examiner
December 10, 2021
- MOF Panel’s Budget Proposal Pushes Macroeconomic Indexing, No Adjustment Rate
December 6, 2021
- MOF Calls for Stepwise Cuts in 2% Adjustment Rate, Timeline towards Abolishment
November 9, 2021
- Japan Drug Spending Up 2.3% Annually Since 2000, Outstripping GDP Growth: MOF
November 9, 2021
- Key MOF Official Wants Budget Neutrality, Cap to Optimize Drug Costs
July 20, 2021
- MOF Panel’s Proposal Urges More Stringent Drug Cost Control, Revisiting of Semi-Automatic Listing
May 24, 2021
- Automatic Listing for Approved Drugs Erodes Financial Predictability: MOF
April 19, 2021
REGULATORY
- Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
- Keytruda SC Heads to Japan Approval, Ipsen’s Ojemda for Conditional Nod
August 25, 2026
- Japan Grants Orphan Tags to Rogocekib, Gildeuretinol, and More
August 25, 2026
- Japan Extends Re-Examination Period for Uplizna
August 25, 2026
- 4 Drug Makers Seek Govt Aid to Upgrade Aging Plants: LDP Hearing
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…